Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-112-7 | CAS number: 91-97-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity:
The acute oral median lethal dose (LD50) of the test material, TODI, in the Sprague-Dawley CD strain rat was found to be greater than 2000 mg/ kg body weight.
Acute inhalation toxicity:
The acute inhalation median lethal concentration (LC50) and 95% confidence limits of the test material TODI, in the Sprague-Dawley Crl : CD ® BR strain rat, were calculated to be:
All animals: 2.74 (1.85 - 4.07) mg/L
Males only: 2.06 (1.37 -3.08) mg/L
Females only: 4.44 (1.55 - 12.7) mg/L
Acute dermal toxicity:
The acute dermal median lethal dose (LD50) of the test material, TODI, in the Sprague-Dawley CD strain rat was found to be greater than 2000 mg/kg body weight.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1997-11-4 to 1997-11-27
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- 1987
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Version / remarks:
- 1993
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd., Margate, Kent, UK.
- Age at study initiation: eight to twelve weeks
- Weight at study initiation: 200 to 242 g (males), 213 to 225 g (females)
- Fasting period before study: overnight fast immediately before dosing
- Housing: in groups of up to five by sex in solid-floor polypropylene cages furnished with woodflakes
- Diet: ad libitum (with exception of an overnight fasting before dosing and three to four hours after dosing)
- Water: ad libitum (with exception of an overnight fasting before dosing and three to four hours after dosing)
- Acclimation period: at least five days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18 to 22
- Humidity (%): 50 to 61
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 200 mg/mL
MAXIMUM DOSE VOLUME APPLIED: 10 mL/kg - Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- five males and five females per dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and mortality: 0.5, 1, 2 and 4 hours after dosing and subsequently once daily for fourteen days
- Frequency of weighing: prior to dosing on Day 0 and on Days 7 and 14
- Necropsy of survivors performed: yes - Statistics:
- Data evaluations included the relationship, if any, between the animals' exposure to the test material and the incidience and severity of all
abnormalities including behavioural and clinical observations, gross lesions, bodyweight changes, mortality and any other toxicological effects.
Using the mortality data obtained, an estimate of the acute oral median lethal dose (LD50) of the test material was made. - Preliminary study:
- No signs of systemic toxicity or deaths were noted at 2000 mg/kg bw (one male and one female rat).
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- >= 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No deaths.
- Clinical signs:
- other: No signs of systemic toxicity.
- Gross pathology:
- No abnormalities were noted at necropsy.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute oral median lethal dose (LD50) of the test material, TODI, in the Sprague-Dawley CD strain rat was found to be greater than 2000 mg/ kg body weight.
- Executive summary:
A study was performed to assess the acute oral toxicity of the test material in the Sprague-Dawley CD strain rat. The method followed that in the OECD Guidelines for Testing of Chemicals No. 401 "Acute Oral Toxicity" (adopted 24 February 1987) and Method B1 of Commission Directive 92/69/EEC (which constitues Annex V of Council Directive 67/548/EEC).
Following a range-finding study, a group of ten fasted animals (five males and five females) was given a single oral dose of test material as a suspension in arachis oil BP at a dose level of 2000 mg/kg bodyweight. The animals were observed for fourteen days after the day of dosing and were then killed and subjected to gross pathological examination.
There were no deaths. No signs of systemic toxicity were noted during the study. All animals showed an expected gain in bodyweight during the study. No abnormalities were noted at necropsy. The acute oral median lethal dose (LD50) of the test material in the Sprague-Dawley CE strain was found to be greater than 2000 mg/kg body weight.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- GLP and guideline compliant
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1997-12-08 to 1998-02-25
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Version / remarks:
- 1981
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.2 (Acute Toxicity (Inhalation))
- Version / remarks:
- 1992
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- traditional method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd, Margate, Kent
- Age at study initiation: eight to ten weeks old
- Weight at study initiation: 253 to 313 g (males), 219 to 253 g (females)
- Housing: in groups of five by sex in sold-floor polypropylene cages with stainless stell lids, furnished with softwood flakes
- Diet: ad libitum (with exception of exposure period)
- Water: ad libitum (with exception of exposure period)
- Acclimation period: at least five days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 ± 2
- Humidity (%): 55 ± 15
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- inhalation: dust
- Type of inhalation exposure:
- nose only
- Vehicle:
- other: unchanged (no vehicle)
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: cylindrical exposure chamber
- Exposure chamber volume: 30 L
- Method of holding animals in test chamber: Each rat was individually held in a tapered, polycarbonate restraining tube fitted onto a single tier of exposure chamber and sealed by means of a rubber 'O' ring.
- Source and rate of air: Compressed air was supplied by means of an oil free compressor and was passed through a water trap and respiratory quality filters before it was introduced to the dust feed.
- Method of conditioning air: Oxygen levels within the exposure chamber were measured by an electronic oxygen analyzer located in the animals’ breathing zone. The test atmosphere was generated to contain at least 19% oxygen.
- Method of particle size determination: Marple Cascade Impactor was used for determination. The sampler was temporarily sealed in a sampling port in the animals’ breathing zone. Exposure chamber air was drawn through the Cascade Impactor using a vacuum pump for a suitable time period. The collection substrates and back up filter were weight before and after sampling and the weight of test material, collected at each stage, calculated by difference.
- Treatment of exhaust air: The concentration within the exposure chamber was controlled by adjusting the rate of the motor and the air flow rate through the chamber. The extract from the exposure chamber passed through a "scrubber" trap and was connected with a hight efficientcy filter to a metered exhaust system.
- Temperature, humidity, pressure in air chamber: 19 - 21°C, 35 - 58%, negative pressure
TEST ATMOSPHERE
- Brief description of analytical method used: The gravimetric method used employed glass fibre filters (Gelman type A/E 25 mm) placed in a filter holder. The holder was temporarily sealed in a vacant port in the exposure chamber in the animals’ breathing zone. Exposure air was drawn through the filter at a measured rate using a vacuum pump for a suitable time period. Each filter was weighed before and after sampling in order to calculate the weight of collected test material. The difference in the two weights divided by the volume of atmosphere sampled was the chamber concentration.
- Samples taken from breathing zone: yes
- Particle size distribution: From the results obtained the distribution of particles in the size range > 10 µm, 10 to 6 µm, 6 to 3.5 µm, 3.5 to 1.6 µm, 1.6 to 0.9 µm and 0.9 to < 0.5 µm was calculated.
- Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- control by adjusting the rate of the motor and the air flow rate through the chamber
- Duration of exposure:
- > 3.9 - < 4.1 h
- Concentrations:
- Mean achieved atmosphere concentration (mg/L):
Dose Group 3: 5.09 mg/L
Dose Group 2: 3.78 mg/L
Dose Group 1: 0.98 mg/L - No. of animals per sex per dose:
- 10 (5 male and 5 female) per dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Day 0, 7 and 14/or death
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other: - Statistics:
- Calculation of the acute inhalation median lethal concentration (LC50) and 95 % conficence limits based on the method of Thompson W R (1947). LC50 and 95 % confidence limits were calculated for males and females separately.
- Preliminary study:
- During characterisation two rats (one male and one female) were exposed to an atmosphere of the test material at a concentration of approximately 5 mg/L for a period of 75 minutes. Severe signs of toxicity were observed and included lethargy, ataxia and laboured respiration. The animals were killed in extremis one hour after removal from the chamber and a gross necropsy was performed. Lung changes were noted and included pallor, generalised speckled appearance and dark foci. Both animals shoed pale kidneys and gaseous distension in the stomach. There were also congestion in the large intestine of the female.
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- >= 1.85 - <= 4.07 mg/L air
- Based on:
- test mat.
- 95% CL:
- > 94 - < 96
- Exp. duration:
- 4 h
- Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- >= 1.37 - <= 3.08 mg/L air
- Based on:
- test mat.
- 95% CL:
- > 94 - < 96
- Exp. duration:
- 4 h
- Key result
- Sex:
- female
- Dose descriptor:
- LC50
- Effect level:
- >= 1.55 - <= 12.7 mg/L air
- Based on:
- test mat.
- 95% CL:
- > 94 - < 96
- Exp. duration:
- 4 h
- Mortality:
- One male was dead on removal from the chamber following exposure to 5.09 mg/L, a second male was found dead 32 minutes after completion of exposure and a third male was killed in extremis one hour after completion of exposure. The follwoing day one male and one female in this dose group were found dead and three animals were killed in extremis. Two females survived.
Following exposure to 3.78 mg/L one male was found dead and two males were killed in extremis on Day 1 following exposure and one female was killed in extremis on Day 12. Two males and four females survived.
No deaths occurred in a group of animals exposed to 0.98 mg/mL. - Clinical signs:
- other: During exposure to 5.09 mg/L wet fur and decreased respiratory rate were commonly observed and several animals showed laboured respiration. On removal from the chamber two surviving males showed extreme lethargy. The other animals were also lethargic and
- Body weight:
- Individual bodyweights were noted.
Incidents of bodyweight loss and reduced bodyweight gain were noted in surviving animals during Week 1 of the study. Normal bodyweight gain was noted during Week 2. - Gross pathology:
- Individual necropsy findings were noted.
The animals that died or were killed in extremis during the study commonly showed lung changes at necropsy which included enlargement, haemorrhagic patches, abnormally dark or reddened appearance, pallor and dark patches. Several dark livers were observed and there were incidents of pale kidneys and gaseous distension in the gastro-intestinal tract. The left eye of one female exposed to 3.78 mg/L was opaque and swollen. In surviving animals dark foci on the lungs were noted in one female exposed to 5.09 mg/L and in two animals exposed to 3.78 mg/L. Several surviving animals including all those exposed to 0.98 mg/L showed no abnormalities at the end of the study. - Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The acute inhalation median lethal concentration (LC50) and 95% confidence limits of the test material TODI, in the Sprague-Dawley Crl : CD ® BR strain rat, were calculated to be:
All animals: 2.74 (1.85 - 4.07) mg/L
Males only: 2.06 (1.37 -3.08) mg/L
Females only: 4.44 (1.55 - 12.7) mg/L - Executive summary:
1. A study was performed to assess the acute inhalation toxicity of the test material, ground, by exposing groups of ten Sprague-Dawley Crl : CD ® BR strain rats (five males and five females) to various concentrations of a dust atmosphere. The animals were exposed for four hours using a nose only exposure system.
The method used followed that described in the OECD Guidelines for Testing of Chemicals (1981) No. 403 "Acute Inhalation Toxicity" referenced as Method B2 in Commission Directive 92/69/EEC "Acute Toxicity - Inhalation" (which constitutes Annex V of Council Directive 67/548/EEC).
2. The mean achieved atmosphere concentrations were as follows:
ATHMOSPHERE CONCENTRATION
GROUP NUMBER
MEAN ACHIEVED mg/L
STANDARD DEVIATION
NOMINAL mg/L
3
5.09
1.07
142.1
2
3.78
0.36
69.9
1
0.98
0.08
16.2
3. The characteristics of the achieved atmospheres were as follows:
GROUP
NUMBER
MEAN ACHIEVED ATMOSPHERE CONCENTRATION (mg/L)
MEAN MASS MEDIAN AERODYNAMIC DIAMETER (μm)
INHALABLE FRACTION
(% <4μm)
GEOMETRIC STANDARD DEVIATION (μm)
3
5.09
6.3
30.2
0.41
2
3.78
5.3
40.0
0.34
1
0.98
3.9
50.6
0.38
4. The mortality data were summarised as follows:
GROUP NUMBER
MEAN ACHIEVED ATMOSPHERE CONCENTRATION(mg/L)
DEATHS
MALE
FEMALE
TOTAL
3
5.09
5/5
3/5
8/10
2
3.78
3/5
1/5
4/10
1
0.98
0/5
0/5
0/10
5. Clinical Observations:
Common abnormalities noted during the study were wet fur, hunched posture, lethargy, pilo-erection, ptosis, decreased respiratory rate and laboured and noisy respiration. Incidents of ataxia, gasping respiration, pallor of the extremities and red/brown staining around the eyes and snout were noted and there were occasional or isolated incidents of extreme lethargy, increased respiratory rate, sneezing, vocalisation upon handling, distended abdomen, tiptoe gait, test material staining around the snout and red/brown staining on the head. One female exposed to 3.78 mg/L showed opacity and swelling to the left eye.
6. Bodyweight
Incidents of bodyweight loss and reduced bodyweight gain were noted in surviving animals during Week 1 of the study. Normal bodyweight gain was noted during week 2.
7. Necropsy
The animals that died or were killed in extremis during the study commonly showed lung changes at necropsy which included enlargement, haemorrhagic patches, abnormally dark or reddened appearance, pallor and dark patches. Several dark livers were observed and there were incidents of pale kidneys and gaseous distension in the gastro-intestinal tract. The left eye of one female exposed to 3.78 mg/L was opaque and swollen. In surviving animals dark foci on the lungs were noted in one female exposed to 5.09 mg/L and in two animals exposed to 3.78 mg/L. Several surviving animals including all those exposed to 0.98 mg/L showed no abnormalities at the end of the study.
8. The acute inhalation median lethal concentration (LC50) and 95% confidence limits of the test material TODI, in the Sprague-Dawley Crl : CD ® BR strain rat, were calculated to be:
All animals: 2.74 (1.85 - 4.07) mg/L
Males only: 2.06 (1.37 -3.08) mg/L
Females only: 4.44 (1.55 - 12.7) mg/L
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 2 006 mg/m³ air
- Quality of whole database:
- GLP and guideline compliant
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1997-11-24 to 1997-12-08
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- 1987
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Version / remarks:
- 1992
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd, Margate, Kent
- Age at study initiation: approximately eight to twelve weeks
- Weight at study initiation: 200 to 212 g (males), 200 to 230 g (females)
- Fasting period before study: none
- Housing: individually during the 24-h exposure and in groups of five, by sex, for the remainder of the study
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: at least five days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18 to 22
- Humidity (%):50 to 72
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12
- Type of coverage:
- semiocclusive
- Vehicle:
- water
- Details on dermal exposure:
- TEST SITE
- % coverage: 10% of the total body surface area
- Type of wrap if used: A piece of surgical gauze was placed over the treatment area and semi-occluded with a pice of self-adhesive bandage. The bandage was further secured with a piece of BLENDERM wrapped around each end
REMOVAL OF TEST SUBSTANCE
- Washing: The treated skin and surrounding hair were wiped with cotton wool moistened with arachis oil BP .
- Time after start of exposure: 24 hours
TEST MATERIAL
- For solids, paste formed: yes (test material was moistened with arachis oil)
- Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg bodyweight
- No. of animals per sex per dose:
- 5 males per dose
5 females per dose - Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations: 0.5, 1, 2, 4 hours after dosing and subsequently once daily for 14 days
- Day 0, 7, and 14
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, dermal reactions, body weight, necropsy - Statistics:
- none
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- None
- Clinical signs:
- other: No signs of systemic toxicity.
- Gross pathology:
- No abnormalities were noted at necropsy
- Other findings:
- None
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute dermal median lethal dose (LD50) of the test material, TODI, in the Sprague-Dawley CD strain rat was found to be greater than 2000 mg/kg body weight.
- Executive summary:
A study was performed to assess the acute dermal toxicity of the test material in the Sprague-Dawley CD strain rat. The method used followed that described in the OECD Guidelines for Testing of Chemicals No. 402 "Acute Dermal Toxicity" (adopted 24 Frebruary 1987) and Method B3 of Commision Directive 92/69/EEC (which constitutes Annex V of Council Directive 67/548/EEC).
A group of ten animals (fivel males and five females) was given a single 24 -hour, semi-occluded dermal application to intact skin at a dose level of 2000 mg/kg bodyweight. The animals were observed for fourteen days after the day of treatment and were then killed for gross pathological examination.
There were no deaths. No signs of systemic toxicity were noted during the study. Very slight to well-defined erythema was noted at the treatment sites of eight animals one day after dosing. No other signs of skin irritation were noted during the study.
All animals showed an expected gain in body weight during the study.
No abnormalities were noted at necropsy.
The acute dermal median lethal dose (LD50) of the test material in the Sprague-Dawley CD strain rat was found to be greater than 2000 mg/kg body weight.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- GLP and guideline compliant
Additional information
Acute toxicity: oral
A study was performed to assess the acute oral toxicity of the test material in the Sprague-Dawley CD strain rat. The method followed that in the OECD Guidelines for Testing of Chemicals No. 401 "Acute Oral Toxicity" (adopted 24 February 1987) and Method B1 of Commission Directive 92/69/EEC (which constitues Annex V of Council Directive 67/548/EEC). Following a range-finding study, a group of ten fasted animals (five males and five females) was given a single oral dose of test material as a suspension in arachis oil BP at a dose level of 2000 mg/kg bodyweight. The animals were observed for fourteen days after the day of dosing and were then killed and subjected to gross pathological examination. There were no deaths. No signs of systemic toxicity were noted during the study. All animals showed an expected gain in bodyweight during the study. No abnormalities were noted at necropsy. The acute oral median lethal dose (LD50) of the test material in the Sprague-Dawley CE strain was found to be greater than 2000 mg/kg bodyweight.
Acute toxicity: dermal
A study was performed to assess the acute dermal toxicity of the test material in the Sprague-Dawley CD strain rat. The method used followed that described in the OECD Guidelines for Testing of Chemicals No. 402 "Acute Dermal Toxicity" (adopted 24 Frebruary 1987) and Method B3 of Commision Directive 92/69/EEC (which constitutes Annex V of Council Directive 67/548/EEC). A group of ten animals (fivel males and five females) was given a single 24 -hour, semi-occluded dermal application to intact skin at a dose level of 2000 mg/kg bodyweight. The animals were observed for fourteen days after the day of treatment and were then killed for gross pathological examination. There were no deaths. No signs of systemic toxicity were noted during the study .Very slight to well-defined erythema was noted at the treatment sites of eight animals one day after dosing. No other signs of skin irritation were noted during the study. All animals showed an expected gain in bodyweight during the study. No abnormalities were noted at necropsy. The acute dermal median lethal dose (LD50) of the test material in the Sprague-Dawley CD strain rat was found to be greater than 2000 mg/kg bodyweight.
Acute toxicity: inhalation
1. A study was performed to assess the acute inhalation toxicity of the test material by exposing groups of ten Sprague-Dawley Crl : CD ® BR strain rats (five males and five females) to various concentrations of a dust atmosphere. The animals were exposed for four hours using a nose only exposure system.
The method used followed that described in the OECD Guidelines for Testing of Chemicals (1981) No. 403 "Acute Inhalation Toxicity" referenced as Method B2 in Commission Directive 92/69/EEC "Acute Toxicity - Inhalation" (which constitutes Annex V of Council Directive 67/548/EEC).
2. The mean achieved atmosphere concentrations were as follows:
ATHMOSPHERE CONCENTRATION | |||
GROUP NUMBER | MEAN ACHIEVED mg/L | STANDARD DEVIATION | NOMINAL mg/L |
3 | 5.09 | 1.07 | 142.1 |
2 | 3.78 | 0.36 | 69.9 |
1 | 0.98 | 0.08 | 16.2 |
3. The characteristics of the achieved atmospheres were as follows:
GROUP NUMBER | MEAN ACHIEVED ATMOSPHERE CONCENTRATION (mg/L) | MEAN MASS MEDIAN AERODYNAMIC DIAMETER (μm) | INHALABLE FRACTION (% <4μm) | GEOMETRIC STANDARD DEVIATION (μm) |
3 | 5.09 | 6.3 | 30.2 | 0.41 |
2 | 3.78 | 5.3 | 40.0 | 0.34 |
1 | 0.98 | 3.9 | 50.6 | 0.38 |
4. The mortality data were summarised as follows:
GROUP NUMBER | MEAN ACHIEVED ATMOSPHERE CONCENTRATION(mg/L) | DEATHS
| ||
MALE | FEMALE | TOTAL | ||
3 | 5.09 | 5/5 | 3/5 | 8/10 |
2 | 3.78 | 3/5 | 1/5 | 4/10 |
1 | 0.98 | 0/5 | 0/5 | 0/10 |
5. Clinical Observations:
Common abnormalities noted during the study were wet fur, hunched posture, lethargy, pilo-erection, ptosis, decreased respiratory rate and laboured and noisy respiration. Incidents of ataxia, gasping respiration, pallor of the extremities and red/brown staining around the eyes and snout were noted and there were occasional or isolated incidents of extreme lethargy, increased respiratory rate, sneezing, vocalisation upon handling, distended abdomen, tiptoe gait, test material staining around the snout and red/brown staining on the head. One female exposed to 3.78 mg/L showed opacity and swelling to the left eye.
6. Bodyweight
Incidents of bodyweight loss and reduced bodyweight gain were noted in surviving animals during Week 1 of the study. Normal bodyweight gain was noted during week 2.
7. Necropsy
The animals that died or were killed in extremis during the study commonly showed lung changes at necropsy which included enlargement, haemorrhagic patches, abnormally dark or reddened appearance, pallor and dark patches. Several dark livers were observed and there were incidents of pale kidneys and gaseous distension in the gastro-intestinal tract. The left eye of one female exposed to 3.78 mg/L was opaque and swollen. In surviving animals dark foci on the lungs were noted in one female exposed to 5.09 mg/L and in two animals exposed to 3.78 mg/L. Several surviving animals including all those exposed to 0.98 mg/l showed no abnormalities at the end of the study.
8. The acute inhalation median lethal concentration (LC50) and 95% confidence limits of the test material TODI, in the Sprague-Dawley Crl : CD ® BR strain rat, were calculated to be:
All animals: 2.74 (1.85 - 4.07) mg/L
Males only: 2.06 (1.37 -3.08) mg/L
Females only: 4.44 (1.55 - 12.7) mg/L
TODI has to be classified for acute inhalation toxicity category 4 (H332: Harmful if inhaled) according to CLP (GHS).
Justification for classification or non-classification
Classification, Labeling, and Packaging Regulation (EC) No 1272/2008
The available data for acute toxicity are reliable and suitable for classification purposes under Regulation (EC) No 1272/2008. Based on this data, the substance is not considered to be classified for acute oral and dermal toxicity under Regulation (EC) No 1272/2008, as amended for the seventeenth time in Regulation (EU) 2021/849. The substance has to be classified for acute inhalation toxicity Cat.4 (H332) under Regulation (EC) No 1272/2008, as amended for the seventeenth time in Regulation (EU) 2021/849.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)